100% Dalts. No mention of the dreaded words - Neurotoxicity and CRS Cytokine Release syndrome (cytokine storm) which are usually associated with Car-T trials. This outcome is exactly what we were looking for in first cohort and low dose. As Timmsy said there was no run-up prior to the results as CHM is still very much flying under the radar. Presentations next week will put more meat on the bone ontop of the announcement tomorrow (8:31am is my guess). Primary endpoints achieved, not long until second cohort results which will tell us much more. Any hint of efficacy in a first cohort is a very good sign and we got that...
This is a long term investment and probably like most here who understand the tech, I will be buying more..
CHM Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)